Enabling CGP from Liquid Biopsy with TruSight Oncology 500 ctDNA v2

November 3, 2023

TruSight™ Oncology 500 ctDNA v2 is now available! Our next version comprehensive genomic profiling (CGP) from liquid biopsy (blood) offers higher analytical sensitivity from lower cfDNA input, faster turn-around time from purified nucleic acid to insights and a more streamlined workflow with automation options coming in 2024! Hear more from early access users at Frederick National Laboratory. Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: facebook.com/illuminainc LinkedIn: linkedin.com/company/illu... Instagram: instagram.com/illuminainc Twitter: twitter.com/illumina #liquidbiopsy #precisionmedicine #CGP #NGS #oncology
Share this article on